GE HealthCare Technologies vs Medtronic
GEHC and MDT side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GEHC and MDT compare
Medtronic is the larger company, worth 3.6 times as much as GE HealthCare Technologies ($123B against $34.6B).
On earnings, GE HealthCare Technologies is cheaper: it trades at 17.6× trailing earnings, against 23.7× for Medtronic.
Medtronic grew revenue faster over the last twelve months (9.8% versus 6.5% for GE HealthCare Technologies).
Medtronic keeps more of each dollar of sales as profit, with a net margin of 13.9% compared with 9.3% at GE HealthCare Technologies.
Both pay dividends: GE HealthCare Technologies yields 0.19% and Medtronic 3.0%.
Medtronic scores higher on the StockData Score (19 against 14 for GE HealthCare Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GEHC | MDT |
|---|---|---|
| Size and price | ||
| Market cap | $34.6B | $123B |
| Share price | $76.57 | $96.54 |
| Change, 1 year | −1.0% | 5.2% |
| Change, 5 years | – | −21.5% |
| Beta (5Y) | 1.20 | 0.52 |
| Employees | 54K | 95K |
| StockData Score | ||
| Total score | 14 | 19 (better) |
| Valuation score | 4 | 5 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 4 | 4 |
| Health score | 2 | 4 (better) |
| Dividend score | 3 | 4 (better) |
| Valuation | ||
| P/E | 17.6× (better) | 23.7× |
| P/S | 1.6× (better) | 3.3× |
| P/B | 3.2× | 2.5× (better) |
| EV/EBITDA | 15.6× | 14.7× (better) |
| P/FCF | 21.9× | 20.1× (better) |
| PEG | 6.91 | 2.43 (better) |
| FCF yield | 4.6% | 5.0% (better) |
| Fair value | $83.67 | $99.74 |
| Margin of safety | 8.5% (better) | 3.2% |
| Growth | ||
| Revenue growth (TTM) | 6.5% | 9.8% (better) |
| Revenue growth, 5Y average | – | 3.8% |
| Net income growth (TTM) | −11.4% | 12.3% (better) |
| EPS growth (TTM) | −10.7% | 12.1% (better) |
| EPS growth, 5Y average | – | 7.0% |
| Profitability | ||
| Gross margin | 39.5% | 65.0% (better) |
| Operating margin | 12.9% | 18.1% (better) |
| Net margin | 9.3% | 13.9% (better) |
| FCF margin | 7.4% | 16.3% (better) |
| Return on equity | 19.2% (better) | 10.7% |
| Return on invested capital | 11.3% (better) | 7.9% |
| Financial health | ||
| Debt / equity | 0.92 | 0.56 (better) |
| Net debt / EBITDA | 2.93 | 1.99 (better) |
| Interest coverage | – | 9.4× |
| Current ratio | 1.26 | 2.07 (better) |
| Altman Z-score | 1.91 | 3.05 (better) |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.19% | 3.0% (better) |
| Payout ratio | 3.2% | 69.8% |
| Years of dividend growth | 2 | 13 (better) |
| Dividend growth, 5Y average | – | 4.1% |
| Buyback yield | 1.2% (better) | 0.95% |
| Shareholder yield | 1.3% | 3.9% (better) |
| Ownership | ||
| Held by institutions | 87.3% | 86.5% |
| Held by insiders | 0.33% | 0.10% |
| Insider net buying, 12 months | $6.4M (better) | −$8.9M |
| Superinvestors holding | 5 | – |
| Short interest, % of float | 4.1% | 3.1% |
Go deeper
- GEHC stock overview
- GEHC income statement
- GEHC valuation and score
- MDT stock overview
- MDT income statement
- MDT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.